Announced Date: 2022-05-06 (May 6, 2022)<\/p>\n\n\n\n
Asset Name: JMKX000623<\/p>\n\n\n\n
Licensor: Shanghai Jemincare Pharmaceutical (China)<\/p>\n\n\n\n
Licensee (Buyer): Orion Corporation (Finland)<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Asset Modality: Small Molecule<\/p>\n\n\n\n
Asset Target: NaV\u00a01.8 blocker<\/p>\n\n\n\n
Potential Indication: treatment of acute and chronic pain<\/p>\n\n\n\n
Current Stage: \u00a0IND approval in China<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Scope of Authority:<\/p>\n\n\n\n
Orion will receive exclusive global development and commersialisation rights, excluding the Greater China area (mainland China, Hong Kong, Macau and Taiwan), for a potent and selective\u00a0NaV\u00a01.8 blocker for the treatment of acute and chronic pain. <\/p>\n\n\n\n
Orion will be fully responsible for its own development and commercialisation costs. In addition, Orion will manufacture the products, including active pharmaceutical ingredient, for its markets.<\/p>\n\n\n\n
Orion will also receive ownership to certain key patent applications relating to the compound within its own territory.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Payment Detail:<\/p>\n\n\n\n
Jemincare will receive\uff1a<\/p>\n\n\n\n
Upfront payment of\u00a0EUR 15 million,<\/p>\n\n\n\n
Development, commercialisation and sales milestone payments, undisclosed.<\/p>\n\n\n\n
Tiered royalty of 8% to 15% on future sales in Orion territory.<\/p>\n\n\n\n
.<\/p>\n\n\n\n
Link:<\/p>\n\n\n\n